Rakhshanda Khan, MD
Family Medicine · Huntsville, ALNPI 1306105341
Payments from drug & device makers
Across 424 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$575
- Pfizer$467
- AstraZeneca$426
- Biohaven Pharmaceuticals, Inc.$384
- Amgen$293
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,79899%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 139 | $1,597 |
| Lilly USA, LLC | 43 | $575 |
| Pfizer | 34 | $467 |
| AstraZeneca | 31 | $426 |
| Biohaven Pharmaceuticals, Inc. | 15 | $384 |
| Amgen | 18 | $293 |
| Kowa Pharmaceuticals America, Inc. | 21 | $273 |
| AbbVie(2 entities) | 20 | $236 |
| Amarin Pharma, Inc. | 13 | $227 |
| GSK | 13 | $188 |
| Boehringer Ingelheim | 12 | $169 |
| Johnson & Johnson | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $135 |
| Sanofi-aventis U.S. LLC | 8 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $97 |
| Astellas Pharma US Inc | 5 | $81 |
| Merck | 5 | $75 |
| Genentech USA, Inc. | 4 | $57 |
| Daiichi Sankyo Inc. | 4 | $56 |
| Novartis | 3 | $51 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Eisai Inc. | 3 | $38 |
| Exact Sciences | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Abbott | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$5,851 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $98,318 |
| JardianceEmpagliflozin | 64 | $71,352 |
| FarxigaDapagliflozin Propanediol | 59 | $46,619 |
| RybelsusSemaglutide | 20 | $40,612 |
| EliquisApixaban | 32 | $37,832 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $21,558 |
| MounjaroTirzepatide | 16 | $16,887 |
| TrulicityDulaglutide | 14 | $13,297 |
| MyrbetriqMirabegron | 25 | $12,943 |
| Telmisartan | 103 | $5,361 |
| Atorvastatin Calcium | 389 | $5,266 |
| SynthroidLevothyroxine Sodium | 49 | $5,122 |
| Rosuvastatin Calcium | 250 | $4,718 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 28 | $3,422 |
| Liothyronine Sodium | 51 | $3,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,597 | $138,930100 claims |
| Boehringer IngelheimJardiance | $169 | $71,35264 claims |
| AstraZenecaFarxiga | $426 | $46,61959 claims |
| PfizerEliquis | $467 | $37,83232 claims |
| Lilly USA, LLCMounjaro, Trulicity | $575 | $30,18430 claims |
| MerckJanumet | $75 | $21,55814 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $12,94325 claims |
| AbbVieSynthroid | $236 | $5,12249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Timothy HowardHuntsville$3M
- Edward WittHuntsville$321K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Jeffrey GarberHuntsville$87K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- Tobin FisherHuntsville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.